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http://dx.dPoor Agreement between Clinician Response Ratings
and Calculated Response Measures in Patients with
Chronic Graft-versus-Host Disease
Jeanne M. Palmer,1 Stephanie J. Lee,2 Xiaoyu Chai,2 Barry E. Storer,2 Mary E. D. Flowers,2
Kirk R. Schultz,3 Yoshihiro Inamoto,2 Corey Cutler,4 Joseph Pidala,5 Mukta Arora,6
David A. Jacobsohn,7 Paul A. Carpenter,2 Steven Z. Pavletic,8 Paul J. Martin2In 2005, a National Institutes of Health consensus conference was held to refine methods for research in pa-
tients with chronic graft-versus-host disease, including proposed objective response measures and a provi-
sional algorithm for calculating organ-specific and overall response. In this study, we used weighted kappa
statistics to evaluate the level of agreement between clinician response ratings and calculated response cat-
egories in patients with chronic graft-versus-host disease. The study included 290 patients who had paired
enrollment and follow-up visits. Based on a set of objective measures, 37% of the patients had an overall com-
plete or partial response, whereas clinicians reported an overall complete or partial response rate of 71%
(slight to fair agreement, weighted kappa 0.20). Agreement rates between calculated organ-specific responses
and clinician-reported changes in skin, mouth, and eyes were fair to moderate (weighted kappa, 0.28-0.54).
We conclude that for both overall and organ-specific comparisons, clinician response ratings did not agree
well with calculated response categories. Possible reasons for this discrepancy include a high clinical sensitivity
for detecting response, a clinical predisposition to recognize selective improvements as overall response, the
large change in objectivemeasures proposed to define response, and the high incidence of progressive disease
based on new manifestations. Conclusions from prior literature reporting high overall response rates based
on clinician judgment would not be supported if the provisional algorithm had been applied to calculate
response. Our analysis also highlights the need to define an overall response measure that incorporates
both patient-reported and objective measures and accurately reflects the outcome in patients with a mixed
response in which one organ or site improves, whereas another shows new involvement.
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Chronic graft-versus-host disease (cGVHD) af-
fects 40% to 70% of patients after allogeneic hemato-
poietic cell transplantation (HCT) and is associated
with significant morbidity and mortality [1]. Histori-
cally, cGVHD was defined as any GVHD occurring
more than 100 days after HCT [2]. In 2005, the Na-
tional Institutes of Health (NIH) formed a consensus
committee to clarify the diagnosis of cGVHD [3].
Rather than being defined as a function of time after
HCT, it was proposed that cGVHD should be defined
according to diagnostic signs such as lichen planus-like
lesions, sclerosis, or fasciitis, or by distinctive manifes-
tations confirmed by biopsy or laboratory testing [3].
The NIH criteria define mild, moderate, and severe
cGVHD according to scores for signs and sym-
ptoms involving skin, fascia and joints, eyes, mouth,1649
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These definitions are predictive of overall survival and
quality of life [4,5]. No widely accepted gold standard
is currently available for determining activity of
cGVHD or the response to treatment. Many clinical
trials have evaluated treatment of cGVHD, but most
relied on the overall judgment of the clinician in
reporting response, and response criteria were not
precisely defined [6-12]. Only a single randomized
study relied on an entirely objective primary
endpoint for measuring treatment success [13]. Gener-
ally, complete resolution of all signs or symptoms has
been classified as complete response (CR), and any sig-
nificant reduction in signs or symptoms without reso-
lution of all manifestations has been classified as partial
response (PR). Progressive disease (PD) has been de-
fined as significant worsening of symptoms or develop-
ment of new organ involvement, while stable disease
has been defined as the absence of significant improve-
ment or worsening.
The 2005NIHconsensus conference addressed the
complex considerations involved in assessing response
to treatment in patients with cGVHD. In its report
[14], the Response Criteria Working Group recom-
mended that the measures used to assess response
should be practical for use both by transplantation
and nontransplantation medical providers, adaptable
for use in adults and in children, and focused on the
most important cGVHDmanifestations.Themeasures
should also give preference to quantitative, rather
than semiquantitative measures, capture information
regarding signs, symptoms, and function separately
from each other, and use validated scales whenever
possible to demonstrate improved patient outcomes to
meet requirements for regulatory approval of novel
agents.TheWorkingGroup proposed a set of objective
measures to be considered for use in clinical trials, and
forms for data collection were developed. Provisional
algorithms for calculating CR, PR, and PD were pro-
posed for each organ and for overall response, based
on the objective response measures [14]. The pro-
visional algorithms to calculate response categories
were based on expert consensus opinion and were
intended to improve consistency in the conduct and re-
porting of cGVHD trials. These definitions were not
intended to be implemented without validation, and
infact are currently being assessed in a largemulticenter
clinical study (BMTCTN 0801: NCT01106833) [15].
In the current analysis, we used data from an ob-
servational study to compare response assessed by
clinicians versus the calculated response categories.
Understanding this relationship will be helpful for
evaluating current therapies when results are analyzed
according to the provisional response categories in
comparison to previously studied therapies in which
response was determined by the clinician’s overall
judgment.METHODS
cGVHD Consortium: Description of Study
Cohort and Cohort for This Analysis
A cohort of HCT recipients affected by cGVHD
was prospectively assembled in a multicenter observa-
tional study [15]. The protocol was approved by the in-
stitutional review board at each site, and all patients
provided written informed consent. Patients enrolled
in the cohort were allogeneic HCT recipients at least
2 years of age with cGVHD requiring systemic immu-
nosuppressive therapy, including both those with
classic cGVHD and those with overlap syndrome.
Cases were classified as incident (enrollment less
than 3 months after cGVHD diagnosis) or prevalent
(enrollment 3 or more months but less than 3 years af-
ter transplantation). Primary disease relapse, inability
to comply with study procedures, and anticipated sur-
vival of less than 6 months were exclusion criteria. At
enrollment and every 6 months thereafter, clinicians
and patients reported standardized information sum-
marizing cGVHD organ involvement and symptoms
after a clinic visit. Patients were allowed to take the
self-administered survey home and return it by mail.
At each time point, the same clinician reported all
the clinician-reported items. Incident cases had an ad-
ditional assessment time point at 3months after enroll-
ment. Objective medical data including ancillary
testing and laboratory results, medical complications,
and medication profiles were abstracted through stan-
dardized medical chart review after each visit. Clini-
cians were not given the calculated NIH overall or
organ-specific response at any time during this study,
nor were they provided with previously completed
study forms.Measures
Several response measures were used in the com-
parisons. (1) Objective response measures and calcu-
lated overall and organ-specific responses. The
objective measures used in this study were derived
from recommendations suggested in part IV of the
NIH Consensus Development Project on Criteria
for Clinical Trials in cGVHD [14]. For example, the
skin assessment was based on the extent of involved
body surface, the eye assessment was based on the
Schirmer test, the oral assessment was based on the
15-point Schubert score, and the liver assessment
was based on laboratory values relative to the upper
limit of normal. Evaluation of the gastrointestinal
(GI) tract used the NIH response scales separately
for the esophagus, upper GI tract, and lower GI tract.
Provisional overall response categories were assigned
based on change from enrollment to follow-up, with
complete resolution of organ dysfunction considered
a CR. The definition of PR was based on the principle
Table 1. Patient Characteristics (N 5 290)
Characteristic Data
Case type, N (%)
Incident 160 (55)
Prevalent 130 (45)
Patient age at enrollment, median years (range) 51 (2-74)
Months from transplantation to enrollment, median (range) 12 (3-39)
Adults, N (%) 279 (96)
Male, N (%) 169 (58)
Disease status, N (%)
Early 101 (35)
Intermediate 127 (44)
Biol Blood Marrow Transplant 18:1649-1655, 2012 1651cGVHD Response Assessmentthat more than 50% relative improvement or 25% ab-
solute improvement from baseline, whichever is
greater, without worsening elsewhere would be evi-
dence of clinical benefit and within the range of detec-
tible change by clinicians [16]. More than 25%
worsening in a previously involved organ was progres-
sion. Because the amount of new organ involvement
that would define PD was not clearly stated in the pro-
visional response algorithm, any new organ involve-
ment at the assessment time compared to baseline
was also considered PD for purposes of this ana-
lysis. All other categories were considered stable dis-
ease. (2) Four-point clinician response assessment
(‘‘4-point assessment’’). At follow-up visits, clinicians
were asked whether the patient had a CR, PR, stable
disease, or PD. (3) Collapsed 8-point clinician re-
sponse assessment (‘‘8-point assessment’’). At follow-
up visits, clinicians assessed their perception of change
in overall GVHD and organ-specific involvement of
skin, mouth, eyes, and fascia and joints on an 8-point
scale, which was categorized as CR (resolved 5 1),
PR (very much better5 2, moderately better5 3), sta-
ble disease (a little better5 4, about the same5 5, a lit-
tle worse 5 6), and PD (moderately worse 5 7, very
much worse 5 8). (4) Change in NIH 0-3 severity
scores. At each assessment time, the clinician deter-
mined overall severity or organ-specific severity on
a scale of 0 to 3 [3]. The overall severity score had
the following descriptions associated with it: none
(0), mild (1), moderate (2), or severe (3). The organ-
specific severity scores were determined by both
physical findings and activity limitations. Change in
severity scores was determined by comparing the en-
rollment and follow-up score. A decrease in the score
to 0 was considered CR. Improvement indicated by
a decrease in the score without a final score of 0 was
considered a PR (for example, a change from 3 at en-
rollment to 2 at follow-up). Worsening indicated by
an increase in the score was considered PD.Advanced 62 (21)
Transplantation source, N (%)
Peripheral blood 260 (89)
BM 19 (7)
Cord blood 11 (4)
Transplantation type, N (%)
Myeloablative 162 (56)
Not myeloablative 128 (44)
Donor match, N (%)
HLA-matched related 141 (49)
HLA-matched unrelated 108 (37)
HLA-mismatched 41 (14)
Donor and recipient gender, N (%)*
Female into male 82 (28)
Other 206 (72)
Prior aGVHD, N (%) 188 (65)
NIH severity score at enrollment, N (%)
None 2 (1)
Mild 37 (13)
Moderate 167 (57)
Severe 84 (29)
BM indicates bone marrow; aGVHD, acute graft-versus-host disease.
*Gender information was not available for 2 donors.Statistical Methods
Patient sociodemographics, transplantation char-
acteristics, and GVHD organ severities at enrollment
were presented as median and range for continuous
variables, and as frequency and percentage for categor-
ical variables.
Agreement between various overall and organ-
specific responses at the 3- or 6-month visit was tested
by weighted kappa statistic for ordinal measures with
Fleiss-Cohen weights [17]. Empirical interpretation
was used for the kappa coefficient (0, no agreement;
0-0.2, slight agreement; 0.2-0.4, fair agreement; 0.4-
0.6, moderate agreement; 0.6-0.8, substantial agree-
ment; and 0.8-1.0, almost perfect agreement). c2 tests
were used to evaluate difference in the proportions of
responses. Results are presented for the entire cohort,although incident and prevalent cases were also ana-
lyzed separately to ensure that conclusions were simi-
lar. Statistical analyses were conducted using SAS/
STAT software, version 9.2 (SAS Institute, IBM,
Armonk, NY).RESULTS
Patient Characteristics
As of September 2010, 290 patients who had at
least one follow-up visit 3 or 6months after enrollment
were included. The median age of these patients was
51 years (range, 2-74 years) (Table 1), 14 patients
were\20 years old at the time of enrollment. At en-
rollment, the sites most frequently affected by
cGVHD were the mouth (62%) and skin (61%).
Less frequently involved organs were the liver (50%),
eye (48%), lung (47%), fascia and joints (28%), and
GI tract (26%).
Response Rates, According to Different Overall
Outcome Measures
Overall CR plus PR rates showed striking differ-
ences, depending on the measure used to evaluate
response, primarily because of differences in the pro-
portion of patients with PR and PD (Table 2). By the
calculated response categories, 37% of the patients
Table 2. Distribution of Response Categories According to
Method of Outcome Assessment
Method of Outcome
Assessment
Response Category
CR (%) PR (%)
Stable
Disease (%) PD (%)
Calculated response 24 (8) 83 (29) 25 (9) 158 (54)
4-point assessment* 31 (11) 171 (60) 30 (10) 56 (19)
Collapsed 8-point
assessment*
19 (7) 117 (41) 127 (44) 22 (8)
Change in overall severity
score*
15 (5) 63 (22) 177 (62) 32 (11)
CR indicates complete response; PR, particle response; PD, progressive
disease.
*Two patients had data missing for the 4-point assessment, 5 patients
had data missing for the 8-point assessment, and 3 patients had data
missing for the change in overall severity score.
Table 3. Characteristics of New Organ Involvement at 3 or
6 Months in Patients Without Progression in a Previously
Involved Site
Organ No. of Patients
NIH Severity
NIH 0 NIH 1 NIH 2 NIH 3
GI tract 30 1 3 17 9
Skin 27 0 2 18 7
Liver 20 0 4 12 4
Eye 11 0 0 9 2
Mouth 7 0 1 4 2
Lung 1 0 0 0 1
NIH indicates National Institutes of Health; GI, gastrointestinal.
1652 Biol Blood Marrow Transplant 18:1649-1655, 2012J. M. Palmer et al.had a CR or PR, much lower than the 71% rate ob-
served with the 4-point assessment (P 5 .004) and
also lower than the 48% rate observed with the col-
lapsed 8-point assessment (P \ .001). These results
demonstrate that the algorithm for calculating re-
sponse is much more stringent than clinician ratings
for concluding response has occurred. In contrast,
the CR plus PR rate derived from the change in overall
severity 0-3 score was 27%, lower than the 37% rate
observed according to the provisional response cate-
gories (P\ .001).
The proportion of patients with PD was substan-
tially higher with the provisional algorithm for calcu-
lating response than with any of the other measures
(Table 2). In many cases, categorization of PD was
based on the development of a new manifestation
that was not reported at the baseline visit. In fact, rais-
ing the threshold to 50% worsening in order to define
PD minimally changed Table 2 (data not shown).
Among 98 patients with discrepant response measures
who had PD according to the calculated response cat-
egories and CR or PR according to the 4-point clini-
cian assessment, PD was based on new organ
involvement in 79 patients (81%), 63 with only a single
new manifestation, 15 with 2 new manifestations, and
1 with 3 new manifestations. Newly involved organs
included the GI tract (n 5 30), skin (n 5 27), liver
(n 5 20), eye as measured by the Schirmer test
(n 5 11), oral cavity (n 5 7), and lung (n5 1). Among
the 85 new manifestations involving the GI tract, skin,
liver, oral cavity, and lung, 11 (13%) had grade 0 or 1
severity according to the NIH 0-3 scale (Table 3).
Among the 11 cases in which the eye was the reason
for PD based on Schirmer test results, only 5 were cat-
egorized as PD based on the NIH 0-3 eye scale, and 2
were not even categorized as abnormal based on the
NIH 0-3 eye scale. Among the 27 patients who had
PD based on new skin manifestations, 15 had different
skin manifestations at the baseline visit (eg, mov-
able sclerosis at baseline, erythema at the follow-up
assessment). If the NIH 0-3 skin score had been usedto measure the skin response for these 15 cases, 4
would have improved, 8 would have remained the
same, and only 3 would have been considered PD.
Overall Response Comparisons
We compared the calculated response categories
to ratings that reflected the clinician impression, mea-
sured as the 4-point assessment, where clinicians cate-
gorized the outcome as CR, PR, stable disease, or PD,
or as the collapsed 8-point assessment. The calculated
response categories did not agree well with either the
4-point assessment, the collapsed 8-point assessment,
or change in overall severity score as indicated by the
low weighted kappa statistics of 0.20, 0.24, and 0.25,
respectively (Table 4). There was better correlation
among the clinician-reported measures. The change
in 0-3 overall severity had moderate agreement with
the 4-point assessment or 8-point assessment, as indi-
cated by the weighted kappa statistics of 0.42 and 0.52,
respectively (Table 4). Results were similar regardless
of whether the same or different clinicians did the en-
rollment and follow-up assessments. The best correla-
tion was seen between the 4-point assessment and the
collapsed 8-point assessment, which are both clinician-
reported measures (weighted kappa 5 0.69).
Organ-Specific Response Comparisons
We also examined the different measures for re-
sponse in each organ individually and compared
them wherever possible. Specifically, calculated re-
sponse categories, clinician assessments, and changes
in severity scores were available for skin, mouth, and
eyes. For the skin, the clinician-response assessment
and the change in severity score showed moderate to
substantial agreement with the calculated response
category, but evaluations of the eyes and mouth
showed only fair to moderate agreement (Table 5).DISCUSSION
Overall comparisons of the response assessments
(CR, PR, stable disease, PD) or perceptions of change
(‘‘completely resolved’’ to ‘‘very much worse’’)
Table 4. Comparisons between Overall Outcome Categories
Comparison
Weighted Kappa
All Evaluations Same Clinician Different Clinician
Calculated response vs 4-point assessment 0.20 0.28 0.11
Calculated response vs collapsed 8-point assessment 0.24 0.28 0.19
Calculated response vs change in overall severity score 0.25 0.35 0.16
4-point vs collapsed 8-point assessment 0.69 0.62 0.75
4-point assessment vs change in overall severity score 0.42 0.45 0.40
8-point assessment vs change in overall severity score 0.52 0.53 0.51
Biol Blood Marrow Transplant 18:1649-1655, 2012 1653cGVHD Response Assessmentreported by clinicians did not agree well with the cal-
culated response categories. These data suggest that
conclusions from prior literature reporting high over-
all CR 1 PR rates based on clinician judgment would
not be supported if the provisional algorithm to calcu-
late response based on objective measures [14] had
been used. Neither the clinician-reported responses
nor the calculated response categories can be consid-
ered to represent a ‘‘gold standard,’’ but our analysis
provides an opportunity to compare them and deter-
mine why such marked differences exist.
Many cases classified as PD by the provisional al-
gorithm were based on the development of mild man-
ifestations in a previously uninvolved site, together
with improvement in other organs. This high propor-
tion of PD contributed to the poor agreement with cli-
nician ratings. In most of these cases, the new
manifestations had grade 1 or 2 severity based on the
NIH 0-3 scale. Clinicians might have concluded that
the effects of new manifestations were outweighed by
improvements in other manifestations. The assess-
ment of overall response is further complicated when
an organ can have multiple manifestations. For exam-
ple, a change from 10% nonmovable sclerosis at base-
line to 8% nonmoveable and 2%moveable sclerosis at
the follow-up assessment could reflect interobserver
variability [18], softening of pre-existing sclerosis (ie,
improvement) or extension of sclerosis into previously
unaffected areas (ie, worsening). In the current analy-
sis, the provisional algorithm would have assignedTable 5. Comparisons between Organ-Specific Outcome Measure
Organ and Outcome Measure
Respo
CR (%) PR (%)
Skin
Calculated response 63 (33) 21 (11)
Collapsed 8-point assessment 49 (24) 49 (24)
Change in 0-3 severity score 55 (27) 27 (13)
Mouth
Calculated response 42 (18) 21 (9)
Collapsed 8-point assessment 42 (18) 82 (36)
Change in 0-3 severity score 56 (27) 24 (11)
Eye
Calculated response 17 (17) 7 (7)
Collapsed 8-point assessment 10 (6) 23 (14)
Change in 0-3 severity score 24 (13) 16 (9)
CR indicates complete response; PR, particle response; PD, progressive diseathis patient to the PD category. In addition, some of
the objective measures might not be reliable. For ex-
ample, the proposed objective scale for ocular involve-
ment is based entirely on the Schirmer test. In
a previous study, we have shown that theNIH 0-3 scale
seems to be the best measure of cGVHD involving the
eye, but this scale does not agree well with results of
the Schirmer test [19]. Finally, clinicians could have at-
tributed new manifestations involving the GI tract or
liver to acute GVHD or other causes that were not
considered relevant to the assessment of cGVHD
[20]. These insights from our study suggest that special
consideration should be taken in situations where one
organ improves significantly, whereas another shows
clinically insignificant worsening. Standardization of
such a response categorization system would likely
be enormously complex.
In attempting to validate the provisional algorithm
for calculating response, we chose the clinician’s per-
ceived assessment of response for comparison, because
this measure clearly has value, especially for purposes
of clinical care. Although this may suggest that we
are advocating clinical judgment as the gold standard,
this endpoint is not sufficiently objective to use as an
endpoint in clinical trials. Clinicians were more likely
to report responses than what was calculated from
the objective measures using the provisional algo-
rithm. In some cases, it seems that clinicians reported
that patients were improving, even when their own
documentation of organ dysfunction at enrollments
nse Category
Stable Disease (%) PD (%) Weighted Kappa
46 (24) 60 (32) Reference
91 (45) 15 (7) 0.54
74 (37) 47 (23) 0.65
132 (57) 37 (16) Reference
94 (41) 11 (5) 0.44
91 (43) 40 (19) 0.45
44 (44) 32 (32) Reference
116 (72) 13 (8) 0.28
79 (43) 64 (35) 0.23
se.
1654 Biol Blood Marrow Transplant 18:1649-1655, 2012J. M. Palmer et al.and follow-up did not support this conclusion. There
was evidence that some clinicians were focusing their
attention on the most bothersome or worrisome man-
ifestation without due consideration of other changes
(eg, liver function tests). It is also possible that the
magnitude of response required for PR according to
the provisional algorithm is too stringent, as suggested
by the high number of patients with stable disease.
Simplification of the criterion to require only an abso-
lute 25% improvement, even in patients with more
than 50% abnormality at baseline, might more accu-
rately reflect the evaluation by clinicians. A study by
Mitchell et al. [16] demonstrated that the minimal de-
tectible change was 10% to 28% of BSA for erythema,
18% to 26% for movable sclerosis, and 17% to 32%
for nonmovable sclerosis. Clinicians might benefit
from training on best practices in performing
a cGVHD evaluation [21] to encourage a comprehen-
sive and systematic approach in assessing treatment re-
sponse. This would also lead to greater precision in
documenting cGVHD manifestations, which would
increase the likelihood that changes in reported organ
involvement reflect change in cGVHD disease activity
and not measurement variations.
This study has several limitations. The frequent
dissociation between the beginning of new treatment
and the baseline evaluation did not mimic conditions
that would apply in the context of a clinical trial, and
the results cannot be used to estimate the response
rates in a clinical trial setting. In our study, clinicians
were asked to assess changes over a 3- to 6-month in-
terval, and the clinician performing the evaluation did
not have access to the previous detailed documentation
by the tools proposed for use in evaluating response.
Clinicians were not asked to apply the proposed algo-
rithms for response assessment and were not given any
training in these calculations. In many cases, the base-
line and subsequent evaluations were done by different
clinicians. Therefore, the clinician ratings depended
on either patient or clinicianmemory or standardmed-
ical record documentation. The number of different
clinicians performing the examinations may be seen
as a weakness, but this reflects clinical practice, and
the objective criteria were designed to provide consis-
tency across providers even if a patient saw different
providers. In addition, the objective measure used for
certain sites of involvement was not optimal, as exem-
plified by the assessment of ocular GVHD. Another
limitation was the low number of pediatric patients
evaluated in this study, making it difficult to apply
these findings to a pediatric population. Although
the inclusion of both incident and prevalent cases
could be questioned, the purpose of our study was
not to determine the actual response rates, but rather
to evaluate the level of agreement between the differ-
ent measures of response that were not affected by
incident vs prevalent status at enrollment. Finally,the measures used for the current study did not include
patient-reported outcomes, including quality of life,
which is the subject of another analysis.
Our current results indicate the need for caution
when results of studies that use the provisional algo-
rithm to calculate response are compared with those
of previous clinical trials that relied primarily on clini-
cian ratings. The Response Criteria Working Group
in the 2005 NIH Consensus Conference on cGVHD
recognized that many outcome measures could be
used to evaluate the response of cGVHD [14], but
the current analysis was focused specifically on clini-
cian response ratings and calculated response mea-
sures. Our results highlight the need to identify the
most reliable and informative clinician-reported and
patient-reported measures of cGVHD activity, so
that changes between the baseline and the assessment
time can be used to assess treatment effect. This mea-
sure should accurately reflect the outcome in patients
with a mixed response where one organ or site im-
proves, whereas another shows new involvement.
More sophisticated algorithms for measurement of re-
sponse should be developed and tested in prospective
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